News

New paper: interactions between oral drug products

2026

When two oral drug products are taken together, they can influence each other physicochemically in the gastrointestinal tract. Christopher Hauß and colleagues measured such interactions in vitro and translated them to humans with PBPK models.

Hauß C, Feick D, Selzer D, Marmol AL, Winter F, Lehr T, Koziolek M. Physicochemical interactions between oral drug products: An integrated in vitro and PBPK modeling approach. Int J Pharm. 2026;704:127375.

Three new doctoral students

Autumn 2026

Dina Hassan, Rama Mohamad and Felix Hauer started their doctorates in Clinical Pharmacy this autumn. Dina Hassan and Rama Mohamad previously completed their master's theses with us. Welcome to the team!

TWIN-EB has started

July 2026

The TWIN-EB project started on 1 July 2026. Using virtual twins of children and adults with recessive dystrophic epidermolysis bullosa, we aim to develop safe, individualised losartan dosing. The project is funded by DEBRA International and LifeArc. Partners are the Medical Center University of Freiburg, Aristotle University of Thessaloniki and the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology in Stuttgart.

Six master's theses completed

2026

Six master's theses were completed in 2026, among them PBPK models of lisinopril, enalapril, melatonin and semaglutide. All theses are listed under Theses.

SafePolyMed: Medication Management Center published

2026

The EU project SafePolyMed has developed the Medication Management Center. The platform helps patients taking many medicines, and the people treating them, to detect drug interactions.

Gepp SC, Schera F, Marok F, Selzer D, Rüdesheim SM, Just KS, Mosch R, Swen JJ, Lehr T, Kiefer S. The SafePolyMed Medication Management Center: A patient-centered platform for improving safety in polypharmacy. Curr Dir Biomed Eng. 2026;12(1):163-166.

PREPARE study: cost-utility analysis published

2026

In the European PREPARE study, a 12-gene panel guided drug therapy. The multinational cost-utility analysis of the study has now been published in eClinicalMedicine.

Fragoulakis V, Swen JJ, … Lehr T, … Mitropoulou C. Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study. EClinicalMedicine. 2026;91:103686.

CONTAIN in JAMA Internal Medicine

2025

In the CONTAIN study, azelastine nasal spray reduced PCR-confirmed SARS-CoV-2 infections from 6.7 to 2.2 percent. The results of the phase 2 trial with 450 participants have been published in JAMA Internal Medicine.

Lehr T, Meiser P, Selzer D, Rixecker T, Holzer F, Mösges R, Smola S, Bals R, CONTAIN Study Group. Azelastine nasal spray for prevention of SARS-CoV-2 infections: A phase 2 randomized clinical trial. JAMA Intern Med. 2025. doi:10.1001/jamainternmed.2025.4283

Four completed doctorates

2025

Christina Kovar, Helena Loer, Nina Scherer and Christiane Dings completed their doctorates in 2025. Congratulations! The thesis titles are listed under Theses.

CYP2D6 network for precision dosing

2025

Simeon Rüdesheim and colleagues developed a PBPK network of CYP2D6 substrates and inhibitors that predicts drug-drug-gene interactions.

Rüdesheim S, Loer HLH, Feick D, Marok FZ, Fuhr LM, Selzer D, Teutonico D, Schneider ARP, Solodenko J, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Schwab M, Lehr T. A comprehensive CYP2D6 drug-drug-gene interaction network for application in precision dosing and drug development. Clin Pharmacol Ther. 2025. doi:10.1002/cpt.3604